Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan;57(1):160.
doi: 10.1111/apt.17282. Epub 2022 Dec 5.

Editorial: ustekinumab during pregnancy-reassuring but still not enough. Authors' reply

Affiliations
Editorial

Editorial: ustekinumab during pregnancy-reassuring but still not enough. Authors' reply

Ariella Bar-Gil Shitrit et al. Aliment Pharmacol Ther. 2023 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Brons G, Cranath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20(6):1091-8.
    1. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734-57.e731.
    1. De Lima A, Zelinkova Z, van der Ent C, Steegers EAP, Van Der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65(8):1261-6.
    1. Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):145-62. e452.
    1. Avni-Biron I, Mishael T, Zittan E, Livne-Margolin M, Zinger A, Tzadok R, et al. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study. Aliment Pharmacol Ther. 2022;56:1361-1369.

LinkOut - more resources